132 related articles for article (PubMed ID: 21820182)
1. Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background?
Fornaro M; Bandini F; Ogliastro C; Cordano C; Martino M; Cestari L; Escelsior A; Rocchi G; Colicchio S; Perugi G
J Affect Disord; 2011 Dec; 135(1-3):154-9. PubMed ID: 21820182
[TBL] [Abstract][Full Text] [Related]
2. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.
Fornaro M; Rocchi G; Escelsior A; Contini P; Martino M
J Affect Disord; 2013 Mar; 145(3):300-7. PubMed ID: 22981313
[TBL] [Abstract][Full Text] [Related]
3. VEGF plasma level variations in duloxetine-treated patients with major depression.
Fornaro M; Rocchi G; Escelsior A; Contini P; Ghio M; Colicchio S; De Berardis D; Amore M; Fornaro P; Martino M
J Affect Disord; 2013 Nov; 151(2):590-595. PubMed ID: 23871390
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
[TBL] [Abstract][Full Text] [Related]
6. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.
Montejo AL; Perahia DG; Spann ME; Wang F; Walker DJ; Yang CR; Detke MJ
J Sex Med; 2011 Mar; 8(3):773-82. PubMed ID: 21091877
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
8. Is duloxetine effective treatment for depression with atypical features?
Stewart JW; Deliyannides DA; McGrath PJ
Int Clin Psychopharmacol; 2008 Nov; 23(6):333-6. PubMed ID: 18854721
[TBL] [Abstract][Full Text] [Related]
9. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
12. BDNF plasma levels variations in major depressed patients receiving duloxetine.
Fornaro M; Escelsior A; Rocchi G; Conio B; Magioncalda P; Marozzi V; Presta A; Sterlini B; Contini P; Amore M; Fornaro P; Martino M
Neurol Sci; 2015 May; 36(5):729-34. PubMed ID: 25501804
[TBL] [Abstract][Full Text] [Related]
13. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
14. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.
Romera I; Pérez V; Menchón JM; Schacht A; Papen R; Neuhauser D; Abbar M; Picard H; Gilaberte I
J Affect Disord; 2012 Dec; 143(1-3):47-55. PubMed ID: 22858211
[TBL] [Abstract][Full Text] [Related]
15. Attributes of response in depressed patients switched to treatment with duloxetine.
Sagman D; McIntosh D; Lee MS; Li H; Ruschel S; Hussain N; Granger RE; Lee AC; Raskin J
Int J Clin Pract; 2011 Jan; 65(1):73-81. PubMed ID: 21078010
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine plasma level and antidepressant response.
De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
